Literature DB >> 33071069

Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies.

Helen Kühn1, Pavel Kolkhir2, Magda Babina3, Miriam Düll1, Stefan Frischbutter3, Jie Shen Fok4, Qingqing Jiao5, Martin Metz3, Jörg Scheffel3, Katharina Wolf1, Andreas E Kremer1, Marcus Maurer6.   

Abstract

The Mas-related G protein-coupled receptor X2 (MRGPRX2) is a multiligand receptor responding to various exogenous and endogenous stimuli. Being highly expressed on skin mast cells, MRGPRX2 triggers their degranulation and release of proinflammatory mediators, and it promotes multicellular signaling cascades, such as itch induction and transmission in sensory neurons. The expression of MRGPRX2 by skin mast cells and the levels of the MRGPRX2 agonists (eg, substance P, major basic protein, eosinophil peroxidase) are upregulated in the serum and/or skin of patients with inflammatory and pruritic skin diseases, such as chronic spontaneous urticaria or atopic dermatitis. Therefore, MRGPRX2 and its agonists might be potential biomarkers for the progression of cutaneous inflammatory diseases and the response to treatment. In addition, they may represent promising targets for prevention and treatment of signs and symptoms in patients with skin diseases or drug reactions. To assess this possibility, this review explores the role and relevance of MRGPRX2 and its activators in cutaneous inflammatory disorders and chronic pruritus.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRGPRX2; MRGX2; agonists; antimicrobial peptides; atopic dermatitis; chronic spontaneous urticaria; eosinophil granule proteins; itch; neuropeptides; pruritus; substance P

Year:  2020        PMID: 33071069     DOI: 10.1016/j.jaci.2020.08.027

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  13 in total

1.  Novel MRGX2 Antagonists for Treating Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-06-21       Impact factor: 4.632

Review 2.  Urticaria.

Authors:  Pavel Kolkhir; Ana M Giménez-Arnau; Kanokvalai Kulthanan; Jonny Peter; Martin Metz; Marcus Maurer
Journal:  Nat Rev Dis Primers       Date:  2022-09-15       Impact factor: 65.038

Review 3.  Mast Cells in the Skin: Defenders of Integrity or Offenders in Inflammation?

Authors:  Martin Voss; Johanna Kotrba; Evelyn Gaffal; Konstantinos Katsoulis-Dimitriou; Anne Dudeck
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 4.  Multifaceted MRGPRX2: New insight into the role of mast cells in health and disease.

Authors:  Saptarshi Roy; Chalatip Chompunud Na Ayudhya; Monica Thapaliya; Vishwa Deepak; Hydar Ali
Journal:  J Allergy Clin Immunol       Date:  2021-05-04       Impact factor: 14.290

Review 5.  Hypersensitivity to non-β-lactam antibiotics.

Authors:  Hans F Merk; David R Bickers
Journal:  Allergol Select       Date:  2022-01-24

Review 6.  Therapeutic Potential of MRGPRX2 Inhibitors on Mast Cells.

Authors:  Hiroyuki Ogasawara; Masato Noguchi
Journal:  Cells       Date:  2021-10-27       Impact factor: 6.600

Review 7.  Antibody or Anybody? Considering the Role of MRGPRX2 in Acute Drug-Induced Anaphylaxis and as a Therapeutic Target.

Authors:  Graham A Mackay; Nithya A Fernandopulle; Jie Ding; Jeremy McComish; Paul F Soeding
Journal:  Front Immunol       Date:  2021-11-19       Impact factor: 7.561

8.  Contemporary Grand Challenges and Opportunities in Skin Allergies.

Authors:  Bettina Wedi
Journal:  Front Allergy       Date:  2021-03-05

9.  Cytokines Stimulated by IL-33 in Human Skin Mast Cells: Involvement of NF-κB and p38 at Distinct Levels and Potent Co-Operation with FcεRI and MRGPRX2.

Authors:  Kristin Franke; Zhao Wang; Torsten Zuberbier; Magda Babina
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923

Review 10.  Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema.

Authors:  Marcus Maurer; Markus Magerl
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-03       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.